Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06157151
Other study ID # PRGN-2009-201
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 2024
Est. completion date January 30, 2028

Study information

Verified date June 2024
Source Precigen, Inc
Contact Amy Lankford
Phone 3015569900
Email clinicaltrials@precigen.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.


Description:

This is a randomized, two-arm study of PRGN-2009 in patients with recurrent or metastatic cervical cancer who are pembrolizumab resistant. Patients meeting all eligibility criteria who consent to participate in the study will be randomized 1:1 to receive a combination of PRGN-2009, plus pembrolizumab, or to receive pembrolizumab alone.


Recruitment information / eligibility

Status Recruiting
Enrollment 46
Est. completion date January 30, 2028
Est. primary completion date January 30, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years and older. - Recurrent or metastatic cervical cancer (histologically or cytologically confirmed) that meets the criteria of pembrolizumab-resistant. - Must have been treated with pembrolizumab, either as monotherapy or in combination - Patients must have received no more than two prior systemic regimens in the recurrent or metastatic setting - Tumors are confirmed positive for PD-L1 and HPV16/18 - Measurable disease that can be accurately measured by RECIST v1.1 criteria - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Life expectancy = 12 weeks from the time of enrollment. - Must have adequate organ function - Negative serum pregnancy test. Women of child-bearing potential (WOCBP) must agree to use adequate contraception prior to study entry and for at least 6 months following completion of study treatment. - All patients must have the ability to understand and willingness to sign a written informed consent. Exclusion Criteria: - Patients with presence of other active malignancy within 1 year prior to study entry - Known Central Nervous System (CNS) disease - Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients. - Known history of active tuberculosis (TB, Bacillus tuberculosis). - Pregnant and lactating women are excluded from this study. - Patients with a history of solid organ transplant. - Patients currently participating in a study of an investigational agent or have used an investigational device within 4 weeks prior to the first dose of study treatment. - Patients, who in the opinion of the investigator, may not be able to comply with the monitoring requirements of the study.

Study Design


Intervention

Biological:
PRGN-2009 plus Pembrolizumab
Subjects randomized will receive PRGN-2009 (5 x 10^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.
Drug:
Pembrolizumab alone
Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.

Locations

Country Name City State
United States National Institute of Health Bethesda Maryland
United States University of Arkansas for Medical Sciences Little Rock Arkansas
United States University of Washington Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Precigen, Inc National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer. The ORR will be calculated as the combination of subjects achieving a complete response or a partial response per RECIST v1.1.
ORR will be calculated and presented with 2-sided 95% confidence interval.
1 year
Secondary Safety of PRGN-2009 in combination with pembrolizumab or pembrolizumab alone Systemic toxicity will be assessed through the capture of Treatment Emergent Adverse Events ( TEAEs). The severity of the TEAEs will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 scale. 1 year
Secondary Progression-Free Survival (PFS) and Overall Survival (OS) following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone Duration of PFS and OS will be summarized using the Kaplan-Meier Product Limit estimator along with the corresponding two sided-95% Confidence intervals. 1 year
Secondary Best Overall Responses (BOR) and Disease Control Rate (DCR) per RECIST v1.1 following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone The proportion of subjects with BOR and DCR will be summarized using descriptive statistics. 1 year
Secondary Time to Response and Duration of Responses following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone TTR and DOR will be summarized using descriptive statistics. 1 year
Secondary Vector shedding following subcutaneous administration of PRGN-2009 Samples collected before and at specific intervals after treatment will be evaluated for presence of adenoviral vector. Up to 4 months
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A